Merger brings OpGen rapid molecular diagnostic tests and additional sales channels.
New test for the Roche serology assay portfolio helps specialists to identify HTLV-I/II infection in donated blood and diagnostic samples.
Sphingotec announces publication of study results showing a strong association between low plasma levels of pro-enkephalin and incident breast cancer.
More than 40 sites are in active evaluation or scheduled to evaluate the sample-to-result test for GBS.
With CLIA waiver, the Alere i Strep A test will be available in a broad range of healthcare settings in the United States, including physician offices, hospital emergency rooms, and retail and walk-in clinics.
DiaSorin and Beckman Coulter have signed a partnership agreement for distribution of automated hepatitis and HIV tests and instruments in China.
Randox is investing £15 million in a new R&D business unit targeting the international market in personalized medicine and companion diagnostics.
Containing a mixture of mutations in key oncogenes and tumor suppressor genes, the biosynthetic reference material is designed to evaluate the performance of next-generation-sequencing-based tumor profiling assays.
A study led by Mayo Clinic researchers has identified a common epigenomic fingerprint and potential target for metastatic cancer therapies.
FlowMetric Diagnostics and Handyem have partnered to develop a mobile point-of-care diagnostic laboratory based on flow cytometry capabilities.
Nova Biomedical, Waltham, Mass, has received FDA clearance for its StatStrip Xpress glucose hospital meter system to be used in all hospital and professional healthcare settings.
In a new position statement, AACC urges support for lab roles in precision medicine.
Featured products include a platelet test from Verax Biomedical, a clinical annotation manager module from Lab7 Systems, and certified clean vials from Wheaton Industries.
New report of patent filings shows Abbott is top filer, followed by University of California.
European study confirms the ability of the Prosigna breast cancer assay to predict response to chemotherapy.
Utilizing lateral-flow technology, the test can provide a result in approximately 20 minutes.
Designed to detect biomarkers and genetic mutations using cell-free DNA liquid biopsies, the kit eliminates the need for invasive and costly tissue biopsies.
The newly approved assay joins an extensive menu of infectious disease tests performed on the Advia Centaur, enabling laboratories to further consolidate their testing onto the platform.
The new test from Roche expands the menu for healthcare-associated infections testing on the widely adopted Cobas 4800 system.
In its latest offering for diabetes testing, Ortho-Clinical Diagnostics meets evolving customer needs with operational, performance, and clinical improvements, and test results free from interference by common hemoglobin variants.